Stock Analiz

Lyell Immunopharma, Inc. LYEL

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$14.30Market cap $352M
Open the interactive analysis →

Lyell Immunopharma, Inc. (LYEL) is a healthcare company listed in the US with a market value of about $352M. In the twelve months to September 30, 2026 it had revenue of $15000 and net income of -$255M, a net margin of -1701066.7%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -66% a year, a 5-year average ROIC of -39%.

About Lyell Immunopharma

Lyell Immunopharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $657000 in 2019 to $36000 in 2025, a decline of about 38.4% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 38% over three years (dilution for shareholders). It spends 440764% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S23,438.0
P/B1.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-39.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-41.0%
Revenue growth (5 yrs, per year)-65.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-301600.0%
ROIC (5-yr avg.)-39.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$15000$36000$61000$130000$85M$11M$8M$657000
Net income-$255M-$274M-$343M-$235M-$183M-$250M-$204M-$129M
Free cash flow-$140M-$151M-$163M-$166M-$194M-$192M-$212M$23M
EPS (diluted)$-12.56$-16.06$-26.23$-18.70$-14.80$-36.80$-313.80$-0.48
Net margin-1701066.7%-762400.0%-562300.0%-180500.0%-216.2%-2349.5%-2636.3%-19692.1%
ROIC—-71.1%-64.1%-27.2%-16.4%-17.0%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $37.62, 163% above the current price; targets range from $12.00 to $49.00; the consensus rating is “Buy”; expected EPS is $-6.69 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Lyell Immunopharma pay a dividend?

Not currently.

Is Lyell Immunopharma a good stock to buy?

We do not give buy or sell advice. Lyell Immunopharma scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.